A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis Source: Eur Respir J, 50 (6) 1701354; 10.1183/13993003.01354-2017 Year: 2017
Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB Source: Eur Respir J, 57 (1) 2001796; 10.1183/13993003.01796-2020 Year: 2021
The main clinical problem of increasing resistance of Mycobacterium tuberculosis (MT) to first-line anti-TB drugs Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005
Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary? Source: Eur Respir J, 54 (4) 1901494; 10.1183/13993003.01494-2019 Year: 2019
Genetic polymorphism and phenotypic resistance of Mycobacterium tuberculosis to fluoroquinolones of different generations Source: Virtual Congress 2021 – Advances in the diagnosis of tuberculosis, multidrug-resistant tuberculosis and nontuberculous mycobacterial disease Year: 2021
The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis Source: Eur Respir J 2012; 39: 626-634 Year: 2012
Change of M. tuberculosis drug susceptibility spectrum during chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 11s Year: 2006
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001
Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR – TB in Iran Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007
Drug-susceptibility testing in tuberculosis: methods and reliability of results Source: Eur Respir J 2005; 25: 564-569 Year: 2005
Association of genetic markers with clinical course of patients with pulmonary tuberculosis with drug resistance Source: Eur Respir J 2007; 30: Suppl. 51, 203s Year: 2007
Rapid molecular detection of rifampicin and isoniazid resistance and identification of mutations in resistant genes of multi-drug resistant tuberculosis (MDR-TB) patients Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis Year: 2011
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009
Patient choice promotes adherence in preventive treatment for latent tuberculosis Source: Eur Respir J 2007; 30: 728-735 Year: 2007
Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance Source: Eur Respir J 2014; 43: 566-581 Year: 2013
Is standardized treatment appropriate for non-XDR multiple drug resistant TB? Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008
Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors Source: Eur Respir J , 49 (3) 1601719; DOI: 10.1183/13993003.01719-2016 Year: 2017
Design of tuberculosis treatment regimens for drug-resistant and intolerant patients – patient and clinician perspectives Source: International Congress 2018 – CC4 Tuberculosis Year: 2018
Considerations upon the drug resistance spectrum of Mycobacterium tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 313s Year: 2001
Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017 Year: 2017